These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6531968)

  • 1. Studies on the reactogenicity and immunogenicity of the BRD-2 and RA27/3 live attenuated rubella vaccines.
    Wang SS; Han YR; Su WN; Chen J; Zhao K
    Vaccine; 1984 Dec; 2(4):277-80. PubMed ID: 6531968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rubella vaccine in the People's Republic of China.
    Han YR; Zhao K; Gong YX; Hao SL; Wang SZ; Wang CT
    Rev Infect Dis; 1985; 7 Suppl 1():S79. PubMed ID: 4001739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rubella outbreak investigation and BRD-II strain rubella vaccine effectiveness study, Harbin city, Heilongjiang province, China, 2010-2011.
    Xu H; Gao X; Bo F; Ma J; Li Y; Fan C; Jiang L; Ma Y; Luo H; An Z
    Vaccine; 2013 Dec; 32(1):85-9. PubMed ID: 24188756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody titres in women six to eight years after the administration of RA2713 and Cendehill rubella vaccines.
    Macdonald H; Tobin JO; Cradock-Watson JE; Lomax J
    J Hyg (Lond); 1978 Jun; 80(3):337-47. PubMed ID: 649946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Wistar RA27/3 rubella virus vaccine in children.
    Balfour HH; Balfour CL; Edelman CK; Rierson PA
    Am J Dis Child; 1976 Oct; 130(10):1089-91. PubMed ID: 973611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fetomaternal apects of immunization with RA27/3 live attenuated rubella virus vaccine during pregnancy.
    Bernstein DI; Ogra PL
    J Pediatr; 1980 Sep; 97(3):467-70. PubMed ID: 7411312
    [No Abstract]   [Full Text] [Related]  

  • 7. Rubella in Orkney: seroepidemiology and vaccination.
    Moffat MA; Heywood SN; Laughton E; Gould JJ; Freestone DS
    J Hyg (Lond); 1977 Jun; 78(3):419-27. PubMed ID: 266542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune response of rubella vaccine in the populations with different age groups].
    Xiong XW; Diao LD; Yan XL
    Zhonghua Liu Xing Bing Xue Za Zhi; 1997 Aug; 18(4):227-9. PubMed ID: 9812525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A serological study on the immunization schedule at first dose of domestic BRD II strain rubella vaccine].
    Xu AQ; Song LZ; Hao SZ
    Zhonghua Liu Xing Bing Xue Za Zhi; 1997 Jun; 18(3):156-9. PubMed ID: 9812464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rubella vaccination in Australia: 2. Experience with the RA27/3 rubella vaccine and results of a double-blind trial in schoolgirls.
    Menser MA; Forrest JM; Bransby RD; Collins E
    Med J Aust; 1978 Jul; 2(3):85-8. PubMed ID: 362141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Rubella vaccine in a rubella outbreak in Guangzhou city, China, 2014.
    Chang C; Mo X; Hu P; Liang W; Ma H; An Z; Liu J; Zheng H
    Vaccine; 2015 Jun; 33(28):3223-7. PubMed ID: 25989448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of vaccine-induced immune responses to rubella: comparison with natural infection.
    Horstmann DM; Schluederberg A; Emmons JE; Evans BK; Randolph MF; Andiman WA
    Rev Infect Dis; 1985; 7 Suppl 1():S80-5. PubMed ID: 4001740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trials with a live attenuated rubella virus vaccine, Cendehill strain.
    Grant L; Belle EA; Provan G; King SD; Sigel MM
    J Hyg (Lond); 1970 Sep; 68(3):505-10. PubMed ID: 5272349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States.
    Plotkin SA; Farquhar JD; Ogra PL
    JAMA; 1973 Aug; 225(6):585-90. PubMed ID: 4740523
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of immunoglobulin M-antibodies after rubella immunization with RA27/3 attenuated live vaccine in teen-agers: remaining problems.
    Braito A; Fanti O; Rossolini GM; Cellesi C
    Boll Ist Sieroter Milan; 1991-1992; 70(1-2):443-8. PubMed ID: 1670047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the teratogenicity of the vaccine strain of the Rubella virus «Orlov-V» (Matonaviridae: Rubivirus: Rubella virus) in experience on rhesus macaques.
    Lavrentjeva IN; Shamsutdinova OA; Chugueva II; Karal-Ogly DD; Vyshemirskiy OI
    Vopr Virusol; 2021 Jan; 65(6):357-363. PubMed ID: 33533577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of antibody 10 years after vaccination with Wistar RA27/3 strain live attenuated rubella vaccine.
    Hillary IB; Griffith AH
    Br Med J; 1980 Jun; 280(6231):1580-1. PubMed ID: 7427177
    [No Abstract]   [Full Text] [Related]  

  • 18. Further evaluation of the optimum age for rubella vaccine administration.
    Wilkins J; Wehrle PF
    Am J Dis Child; 1979 Dec; 133(12):1237-9. PubMed ID: 517472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women.
    Tingle AJ; Mitchell LA; Grace M; Middleton P; Mathias R; MacWilliam L; Chalmers A
    Lancet; 1997 May; 349(9061):1277-81. PubMed ID: 9142061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. History of RA27/3 rubella vaccine.
    Plotkin SA; Buser F
    Rev Infect Dis; 1985; 7 Suppl 1():S77-8. PubMed ID: 3890107
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.